Linda Nadwodny, DO
Family Medicine · Lansdale, PANPI 1386606051
Payments from drug & device makers
Across 145 payments — averaging $17.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$666
- Pfizer$327
- Novo Nordisk$164
- Merck$132
- GSK$125
- Amgen$105
- plus $988 from 27 others
What the payments were for
- Food & beverage$2,508100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 37 | $666 |
| Pfizer | 23 | $327 |
| Novo Nordisk | 10 | $164 |
| Merck | 9 | $132 |
| GSK | 6 | $125 |
| Amgen | 6 | $105 |
| AstraZeneca(2 entities) | 6 | $101 |
| Johnson & Johnson | 7 | $99 |
| Boehringer Ingelheim | 4 | $85 |
| Daiichi Sankyo Inc. | 4 | $82 |
| Inspire Medical Systems, Inc. | 3 | $59 |
| Abbott | 3 | $57 |
| Novartis | 2 | $45 |
| Amarin Pharma, Inc. | 3 | $42 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $42 |
| Dexcom, Inc. | 1 | $39 |
| Sanofi Pasteur Inc. | 2 | $36 |
| Coloplast | 1 | $34 |
| Medtronic | 2 | $31 |
| Verona Pharma, Inc. | 1 | $28 |
| Biogen | 1 | $22 |
| Pulmonx Corporation | 1 | $21 |
| Aimmune Therapeutics, Inc. | 1 | $21 |
| Exact Sciences | 1 | $19 |
| Paratek Pharmaceuticals, Inc. | 1 | $17 |
| Qiagen, LLC | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Lilly USA, LLC | 1 | $15 |
| Hologic Sales And Service, LLC | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
| Genentech USA, Inc. | 1 | $12 |
| Mayne Pharma Commercial LLC | 1 | $12 |
| Dynavax Technologies Corporation | 1 | $10 |
How this compares
$2,508 in reported general payments places this provider in the 80th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 101 | $145,915 |
| JardianceEmpagliflozin | 86 | $111,549 |
| TrulicityDulaglutide | 76 | $107,707 |
| MounjaroTirzepatide | 43 | $46,632 |
| JanuviaSitagliptin Phosphate | 19 | $28,352 |
| JanumetSitagliptin Phos/Metformin Hcl | 20 | $20,120 |
| ProliaDenosumab | 11 | $19,014 |
| RybelsusSemaglutide | 11 | $16,870 |
| Valsartan | 274 | $14,390 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 20 | $10,817 |
| Rosuvastatin Calcium | 659 | $9,518 |
| SynthroidLevothyroxine Sodium | 127 | $8,248 |
| EliquisApixaban | 14 | $7,972 |
| Atorvastatin Calcium | 649 | $7,846 |
| Levothyroxine Sodium | 606 | $7,720 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $164 | $162,785112 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $15 | $154,339119 claims |
| Boehringer IngelheimJardiance, Tradjenta | $85 | $117,35997 claims |
| MerckJanuvia, Janumet | $132 | $48,47239 claims |
| GSKAnoro Ellipta, Breo Ellipta, Incruse Ellipta | $125 | $22,18048 claims |
| AmgenProlia | $105 | $19,01411 claims |
| AbbVieSynthroid | $666 | $8,248127 claims |
| PfizerEliquis | $327 | $7,97214 claims |
| Johnson & JohnsonInvokana | $99 | $6,43011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Lansdale
- Robert DetweilerLansdale$684K
- Evan KesslerLansdale$231K
- Michael ParkeLansdale$119K
- Jack RosenfeldLansdale$95K
- Kem YenalPhila$12.6M
- Marcy FleckerSmithfield$6.9M
- Tiffany PlutoScottdale$4.8M
- Bryce PalchickPittsburgh$4.7M
- Harris CohenHorsham$3.7M
- Shari RozenPittsburgh$2.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.